Search filters

List of works by Luca Malorni

A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients

scientific article published on 22 March 2018

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer

scientific article published on 13 September 2016

A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.

scientific article

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)

scientific article published on 11 December 2019

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

scientific article published on 10 March 2016

Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?

scientific article

Cell-Free DNA-Methylation-Based Methods and Applications in Oncology

scientific article published on 15 December 2020

Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

scientific article published on 26 May 2015

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

scientific article

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

scientific article

Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer

scientific article published on 11 June 2019

Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy.

scientific article

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers

scientific article

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial

scientific article published on 07 December 2013

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.

scientific article published on 8 January 2018

Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib

scientific article published on 10 March 2020

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients

scientific article published on 9 December 2014

Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer?

scientific article

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

scientific article published on 10 December 2018

Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.

scientific article published on 27 October 2017

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

scientific article published on 23 July 2019

New approaches for improving outcomes in breast cancer in Europe

scientific article published on 31 March 2015

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

scientific article published on 01 August 2018

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

scientific article published on 14 January 2020

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.

scientific article published on 27 March 2018

Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature

scientific article published on 01 August 2018

Polyendocrine Treatment in Estrogen Receptor–Positive Breast Cancer: A “FACT” Yet to Be Proven ⬇️

scientific article published on April 30, 2012

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)

scientific article published on 03 May 2019

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy

scientific article published on 28 November 2019

The continued evidence from overviews: what is the clinical utility?

scientific article published on August 2013

The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review

scientific article published on 25 January 2019

The role of abemaciclib in treatment of advanced breast cancer.

scientific article published on 31 May 2018

TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.

scientific article published on 16 May 2016

Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis.

scientific article published on 08 October 2009

What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?

scientific article published on 11 February 2020

ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data

scientific article published on 24 December 2018

Paulina is supported by:

About Paulina

Help